CClinicalTrials.gg
CompletedNCT04963556Updated Jul 15, 2021

Effects of Red Bull® on the Effects of Training and Haemodynamic Parameters

An interventional study of Red Bull in Effects of; Food, Allergic, sponsored by University of Basel. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by University of Basel · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Jun 2017, registered Nov 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Background:

The consumption of Energy Drinks (EDs) can acutely lead to negative side effects, such as raised blood pressure and impaired endothelial function. Nevertheless, they are sold worldwide and are often consumed before physical activity (PA). In contrast to the blood pressure elevating effect of EDs, PA leads to a reduction of blood pressure. The effect of ED consumption on blood pressure response during and after endurance training is currently unresolved.

Methods:

A total of 23 participants (eleven men, twelve women) were evaluated in the intervention study with a blinded Cross-Over Design. They consumed on two different days either 355 ml Red Bull (RB) or 355 ml Placebo (Pla) in randomised order. The peripheral (PBP) and central blood pressure (CBP) were measured before, during and after a 30-minute aerobic endurance training, by the Schiller BR-102 plus PWA device.

Read the detailed description

Background:

The consumption of Energy Drinks (EDs) can acutely lead to negative side effects, such as raised blood pressure and impaired endothelial function. Nevertheless, they are sold worldwide and are often consumed before physical activity (PA). In contrast to the blood pressure elevating effect of EDs, PA leads to a reduction of blood pressure. The effect of ED consumption on blood pressure response during and after endurance training is currently unresolved.

Methods:

A total of 23 participants (eleven men, twelve women) were evaluated in the intervention study with a blinded Cross-Over Design. They consumed on two different days either 355 ml Red Bull (RB) or 355 ml Placebo (Pla) in randomised order. The peripheral (PBP) and central blood pressure (CBP) were measured before, during and after a 30-minute aerobic endurance training, by the Schiller BR-102 plus PWA device.

02

Conditions studied

  • Effects of; Food, Allergic
03

In context

Lead sponsor

University of Basel is the lead sponsor of 61 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • No known cardiovascular diseases such as arterial hypertension and diabetes mellitus.
  • No ophthalmological diseases such as glaucoma or macular degeneration.
  • No regular medication
  • No vasodilator abuse for 24 h before the respective intervention (e.g. smoking, use of stimulants, β-blockers).
  • No pregnancy (anamnestic)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Red Bull

    Drinking of 355 ml Red Bull

    Dietary Supplement: Red Bull

  • Placebo comparator
    Placebo

    Drinking of 355 ml sweetened water

    Dietary Supplement: Red Bull

Interventions

  • Dietary supplementRed Bull

    Drinking of Red Bull before exercise

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Effect on blood pressure

    Effect on systolic and diastolic blood pressure

    Time frame: 24 hours

Secondary outcomes

  1. Pulse wave velocity

    central pulse wave velocity

    Time frame: 24 hours

07

Study locations

1 site
  • University of Basel
    Basel, 4052, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04963556
Lead sponsor
University of Basel
Responsible party
Arno Schmidt-Trucksäss (Prof. Dr. med., University of Basel) — Principal investigator
First posted
Jul 15, 2021
Start date
Jun 18, 2017
Primary completion
Nov 1, 2017
Completion
Apr 15, 2018
Last update
Jul 15, 2021

Study contacts

Arno Schmidt-Trucksäss, MD
principal investigator · University of Basel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion